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OBJECTIVES We studied the effects of N-acetyl-cys-asn-(5,5-dimethyl-4-thiazolidine-carbonyl)-4-amino-
methyl-phe-gly-asp-cys, monoacetate (MK-0852) (platelet GPIIb/IIIa receptor blocker) on
peak reactive hyperemia, distribution of blood flow, regional contractile function and infarct
size in a canine model of acute ischemia-reperfusion injury.
BACKGROUND Platelet activation and formation of platelet microaggregates in coronary vessels could
contribute to ischemia-induced myocyte injury. Inhibition of platelet aggregation could
reduce ischemia-reperfusion injury.
METHODS Three groups of dogs (n 5 10/group) were studied; group 1—heparin (HEP) (100 U/kg/h
intravenously), group 2—MK-0852 (300 mg/kg intravenous bolus followed by 3 mg/kg/min
for 3 h) and group 3—MK-0852 plus HEP. Infarct size after 60 min regional ischemia and
3 h reperfusion was evaluated by tetrazolium staining and normalized to risk area (Monastral
blue dye).
RESULTS Infarct size in HEP-treated controls was 32.4 6 2.8%; in MK-0852 without or with HEP
groups, infarct size was 17.4 6 1.9% (p 5 0.001) and 23.4 6 3.0% (p 5 0.04), respectively.
Cardiac hemodynamics and rate-pressure product were comparable between groups. Multi-
variate analysis using collateral blood flow as the independent variable confirmed the
cytoprotective actions of MK-0852. Postischemic peak reactive hyperemia in the infarct-
related artery was depressed in all groups; during reperfusion, transmural distribution of
myocardial blood flow returned to near control levels, but severe regional hypokinesia
persisted.
CONCLUSIONS Diminished infarct size with MK-0852 treatment suggests an additional mechanism of
benefit for GPIIb/IIIa blockers beyond stabilization of a “culprit” acute coronary lesion. This
cytoprotective effect was unrelated to preservation of coronary vasoreactivity (assessed by
reactive hyperemia), restoration of blood flow across the myocardium or acute improvement
in contractility. (J Am Coll Cardiol 2000;36:2317–24) © 2000 by the American College of
Cardiology
Early restoration of arterial patency during acute myocardial
infarction (MI) with thrombolysis or angioplasty signifi-
cantly limits myocardial necrosis. This beneficial effect may
be blunted by acute or subacute reocclusion or by the more
protracted process of postangioplasty restenosis. Activated
platelets participate in intravascular thrombus formation;
they may: 1) cause reocclusion of the “culprit” coronary
artery lesion, 2) form embolic aggregates compromising
myocardial perfusion thereby exacerbating the effects of
ischemia and 3) release vasoactive substances that may
adversely affect downstream perfusion as well as have
deleterious electrophysiologic effects. A common pathway
for all platelet agonists has recently been described (1); the
platelet-glycoprotein IIb/IIIa complex (GPIIb/IIIa) in ac-
tivated platelets binds the soluble adhesive proteins fibrin-
ogen, von Willebrand factor, fibronectin and vitronectin.
Clinical studies using either monoclonal antibodies (2,3)
or other selective GPIIb/IIIa receptor antagonists have
shown promise in reducing the complications associated
with acute coronary syndromes (4–7) and with percutane-
ous coronary interventions (8) including refractory angina,
MI and mortality in unstable angina and non-Q wave
myocardial infarct patients without significant increases in
bleeding (6–8). Studies in whole animals have reported
antinecrosis and antiarrhythmic effects of platelet activating
factor blockers (9–13). In this study we examined whether
blockade of GPIIb/IIIa receptors by N-acetyl-cys-asn-(5,5-
dimethyl-4-thiazolidine-carbonyl)-4-amino-methyl-phe-
gly-asp-cys, monoacetate (MK-0852) would limit infarct
size and modify the potentially deleterious consequences of
increased intravascular platelet aggregation on coronary
reactive hyperemia and regional myocardial contractile
function.
METHODS
All procedures used in this study are in accordance with the
“Guide to the Care and Use of Experimental Animals”
(Vols. 1 and 2) of the Canadian Council on Animal Care;
the Laval University Animal Ethics Committee also ap-
proved these studies. Thirty-six adult mongrel dogs of either
sex (weight 20 to 25 kg) were premedicated with diazepam
(1 mg/kg intravenous) and fentanyl (20 mg/kg intravenous)
and then anesthetized using sodium pentobarbital
(25 mg/kg intravenous). Dogs were intubated and mechan-
ically ventilated; end-expiratory pressure was maintained at
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5 to 7 cm H2O. Saline was administered intravenously at
100 mL/h to replace fluid loss. A splenectomy was per-
formed to prevent significant alterations in blood volume
and hematocrit (14). Body temperature was kept between
37.5 to 38.5°C by a water-jacketed Micro-Temp heating
unit (Zimmer, Dover, Ohio) since temperature-induced
variability during ischemia-reperfusion may be an important
predictor of myocyte necrosis (15).
A left thoracotomy was performed in the fifth intercostal
space. Polyethylene catheters (7F) were inserted into the
internal thoracic artery, the left atrium and in both femoral
arteries and veins for administration of drugs and fluids. A
5F microtipped pressure transducer (Millar Instruments,
Inc., Houston, Texas) was placed in the left ventricle (LV)
cavity through the apex to measure LV pressure and its first
derivative; a 7F pigtail catheter was advanced to the aortic
root via the left femoral artery. A segment of the main
circumflex artery was isolated proximal to its first major
marginal branch. Coronary blood flow was measured by
transit time flowmetry (T206, Transonic Systems Inc.,
Ithaca, New York). The Transonic flowmeter uses wide-
beam ultrasonic illumination to provide a measure of vol-
ume flow in mL/min. A catheter (22 intracath) was inserted
in the lumen of the left circumflex artery immediately distal
to the snare occluder and flowmeter (16).
Ultrasonic crystals (Triton Technologies, San Diego,
California) were positioned in the midmyocardium of the
ischemic and nonischemic perfusion beds as previously
described (17). The chest cavity was then covered with
plastic film to prevent myocardial cooling.
Experimental design. Dogs were allowed to stabilize for
20 min; under steady-state hemodynamic conditions (i.e.,
baseline and every 30 min during reperfusion) the left
circumflex artery was occluded for 20 s to assess the reactive
hyperemic response of the infarct-related artery as described
previously (18,19).
Dogs were subjected to 60 min regional coronary occlu-
sion, randomly divided (by rotation through the various
treatments) to three study groups and given: 1) heparin
(HEP; 100 U/kg/h intravenously), 2) MK-0852 (300 mg/kg
intravenous bolus over 3 min followed by 3 mg/kg/min for
3 h) and 3) HEP plus MK-0852 (as per groups 1 and 2).
Treatment was initiated at the onset of coronary reperfusion
(REP) and continued for 3 h. This MK-0852 dosage
schedule has previously been shown to be beneficial in
canine thrombosis models (20). Dogs were also given
lidocaine (10 mg intravenous bolus) at 30 min coronary
occlusion, 5 min before and at 5 and 10 min of REP. Hearts
that went into ventricular fibrillation were cardioverted (DC
shock #50 J); when hearts could not be defibrillated after
two attempts, the animal was euthanized and not entered
into the data analysis.
Measurement of ex vivo platelet aggregation. In a parallel
study, dogs (n 5 4) were given MK-0852 as described
earlier. Blood (5 mL) was collected from an indwelling
femoral vein catheter into Vacutainer tubes containing
0.5 mL of 3.8% sodium citrate; after collection (0, 10, 30,
60, 120 min) platelet aggregation in whole blood was
assessed by the impedance method of Cardinal and Flower
(21) using a whole blood aggregometer (Model 592,
Chrono-Log, Pennsylvania).
Flow cytometric analysis of platelet aggregation and
activation. Flow cytometric measurements were done us-
ing a modification of the method recently described by Jy
and coworkers (22); platelet activation was assessed in
platelet rich plasma (PRP) prepared by centrifugation of
citrated whole blood at 1,000 rpm for 10 min. To 50 mL
PRP was added 5 mL FITC a-CD41 to label platelets; after
10 min orbital shaking at 120 rpm at room temperature,
samples were incubated with collagen (final concentration
5 mg/mL) and further shaken for 5 min. The reaction was
stopped by the addition of p-formaldehyde (2% final con-
centration), incubated for 10 min and diluted with 1.0 mL
of PBS. The antibodies used were an antihuman CD41
(clone SZ22), a murine IgG1 monoclonal antibody that
specifically binds to GPIIb receptors (Coulter-Immunotech,
Burlington, Ontario) and antihuman CD 62P (clone CLB-
Thromb/6; canine CD 62P was not available), a murine
IgG1 monoclonal antibody that recognizes P-selectin; nei-
ther of these antibodies inhibited platelet aggregation in-
duced by collagen. All antibodies were used at optimum
concentration for maximum fluorescence and minimal non-
specific binding.
Samples were analyzed within 2 h of collection in a
Coulter EPICS Elite ESP flow cytometer (Coulter Corp.,
Hialeah, Florida) equipped with a 100-mV argon laser to
produce a laser beam at 488 nm, detecting FITC and PE
fluorescence at band-pass filters of 525 and 575 nm,
respectively. Five thousand platelets were analyzed by for-
ward and side scatter; identity was confirmed using the
anti-GPIIb monoclonal antibody, CD41. An electronic bit
map was set around the platelet population and adjusted for
each sample to ensure that .98% of the particles analyzed
were positive for GPIIb.
Hemodynamic measurements. Standard lead II of the
scalar electrocardiogram was used to determine heart rate.
Heart rate, arterial pressures, coronary flow and myocardial
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segment lengths were measured throughout the experimen-
tal protocol. All analog data were recorded on a 12-channel
direct-writing oscillograph (Yokogawa OR1200A; Electro-
Meters, Dorval, Canada) and on videotape using a TEAC
XR-510 recorder.
Measurement of regional myocardial blood flow. Re-
gional myocardial blood flow was determined using 15 mm
microspheres suspended in saline (NEN, Boston, Massa-
chusetts) and labeled with 113Sn, 85Sr, 95Nb or 46Sc.
Microspheres were agitated with a vortex agitator before
injection through the left atrial cannula and flushed with
15 mL normal saline. Reference arterial blood was with-
drawn from the internal thoracic artery cannula at a rate of
7.5 mL/min beginning 10 s before microsphere injection
and continuing for 2 min. Myocardial blood flow was
evaluated at baseline, 30 min coronary occlusion and
180 min REP.
Infarct and risk zone analysis. At the end of each study
the circumflex coronary artery was ligated at the site of
previous occlusion, and 10 mL of Monastral blue dye was
injected via the atrial catheter to delineate the area at risk.
Under deep pentobarbital anesthesia, cardiac arrest was
induced by intraatrial injection of saturated potassium chlo-
ride. A 1.5% solution of warmed (37°C) 2,3,5-
triphenyltetrazolium chloride was infused into the ischemic
region via the coronary artery cannula (distal to the snare
occluder) for a period of 30 min. The heart was rapidly
excised and rinsed in saline at room temperature; atria, large
Figure 1. Effects of MK-0852 on collagen-induced platelet glycoprotein IIb/IIIa receptor activation. Platelet rich plasma from venous blood (i.e., from the
ischemic zone) was prepared as described in the Methods section. Some spontaneous platelet aggregation was observed before the addition of collagen
(5 mg/mL) in vehicle treated dogs (A); this did not occur after administration of MK-0852 (C). Collagen induced significant platelet aggregation in vehicle
treated dogs (B), but this reaction was significantly blunted with MK-0852 treatment (D). MK-0852 5 N-acetyl-cys-asn-(5,5-dimethyl-4-thiazolidine-
carbonyl)-4-amino-methyl-phe-gly-asp-cys, monoacetate.
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epicardial vessels and right ventricle were removed, and the
LV was fixed in 10% buffered formaldehyde. The LV was
cut from apex to base, and the outline of each slice, the
necrotic area and risk area were traced onto acetates. The
LV area, risk area and necrotic area were determined using
a digitizing tablet (Summagraphics II Plus; Seymour, Con-
necticut) interfaced with a personal computer and analyzed
with SigmaScan software (SPSS Inc., California). Results
are expressed as the risk area indexed to total LV mass and
the area of necrosis indexed to either risk area or total LV
mass.
Regional myocardial blood flow and reactive hyperemic
response. Tissue samples from the central portion of the
nonischemic and ischemic zones were subdivided into
endocardial, midmyocardial and epicardial segments. Myo-
cardial tissue from the lateral border zones was discarded to
avoid potential cross-contamination. Radioactivity in myo-
cardial tissue and blood reference samples was measured in
a gamma-well scintillation counter (Cobra II, Canberra
Packard Instruments, Montreal, Canada) with standard
window settings. Tissue counts were corrected for back-
ground, decay and isotope spillover; regional myocardial
blood flow was calculated with computer software (PCG-
ERDA, Packard Instruments, Montreal, Canada) and ex-
pressed as mL/min/g of myocardium.
Control and peak hyperemia blood flow were directly
determined from strip chart recordings. Peak flow is the
maximum mean flow during the reactive hyperemia re-
sponse; this value was normalized to baseline values using
the equation: [peak flow-control flow/control flow] 3
100%.
Cardiac hemodynamics and systolic fractional shorten-
ing. Heart rate and arterial blood pressure were measured
and averaged over five continuous beats during normal sinus
rhythm. Left ventricular dP/dt was used to define the
timing of the cardiac cycle for segment length measure-
ments; systolic fractional shortening was calculated as pre-
viously described (23).
Data analysis. Cardiac hemodynamic parameters, coronary
blood flow and myocardial contractile function during
control conditions and after administrations of the respec-
tive pharmacologic treatments were evaluated using analysis
of variance for repeated measures. When a significant effect
of treatment was obtained, comparisons within experimen-
tal groups were made using Scheffe’s post-hoc test. Myo-
cardial blood flow and infarct size were compared by
analysis of variance. The relation between infarct size and
blood flow within the ischemic zone was initially analyzed
by analysis of covariance for linear regressions; infarct size
(normalized to risk area) was the dependent variable, and
Figure 2. Changes in rate-pressure product during the ischemia-
reperfusion protocol. Controls (i.e., heparin; open circles), MK-0852 plus
heparin (open squares), MK-0852 (open triangles); the same symbols are
used to identify each treatment group in all figures. I 5 ischemia; R 5
reperfusion. Data are means 6 standard error of the mean.





HEP 10 126 6 17 145 6 19 146 6 19 152 6 19 148 6 20
MK 10 126 6 31 135 6 25 136 6 34 135 6 39 145 6 45
MK 1 HEP 10 120 6 13 130 6 23 145 6 42 151 6 64 158 6 57
Mean arterial pressure
(mm Hg)
HEP 10 93 6 13 79 6 13 79 6 6 80 6 7 78 6 7
MK 10 91 6 11 83 6 8 80 6 7 81 6 10 76 6 12
MK 1 HEP 10 85 6 7 81 6 6 81 6 12 76 6 12 71 6 14
Diastolic coronary perfusion
pressure (mm Hg)
HEP 10 85 6 13 12 6 2* 67 6 6 67 6 7 67 6 7
MK 10 84 6 9 14 6 3* 68 6 6 70 6 10 65 6 15
MK 1 HEP 10 79 6 8 14 6 4* 72 6 13 64 6 15 60 6 14
Coronary blood flow
(mL/min)
HEP 10 43 6 15 0 6 0* 76 6 23 69 6 24 56 6 21
MK 10 44 6 19 0 6 0* 65 6 25 63 6 30 64 6 33
MK 1 HEP 10 39 6 12 0 6 0* 72 6 19 64 6 19 52 6 18
Data are mean 6 1SD. *p # 0.05. HEP 5 heparin.
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blood flow within the inner two-thirds of the LV wall was
the covariate. Since we were unable to reproduce the classic
inverse relation between infarct size and subendocardial
blood flow due to the narrow range of blood flow values
(0.03 to 0.10 mL/min/g), a multivariate analysis was done
to ascertain possible differences in infarct size. All statistical
procedures were performed using the SAS statistical soft-
ware package (SAS Inc., Cary, North Carolina). A p value
less than 0.05 was used to indicate a significant difference in
mean values.
RESULTS
Thirty-six dogs were entered into the study. One was
excluded due to an absent reactive hyperemic response
(possibly due to high coronary collateral blood flow levels in
the ischemic zone). Five dogs could not be resuscitated after
two attempts at cardioversion and succumbed to ventricular
fibrillation. Data are reported for 30 dogs that completed
the protocol.
Platelet aggregation and activation. Platelet aggregation
in whole blood was completely abolished by MK-0852.
Flow cytometry was also used to examine platelet aggrega-
tion and activation of CD41, a pan-platelet marker, in PRP
(Fig. 1). Before MK-0852 treatment (Fig. 1A) some spon-
taneous platelet aggregation occurred in the absence of
collagen; addition of collagen increased both side-scatter
and CD41 fluorescence indicating enhanced platelet aggre-
gation (Fig. 1B). No spontaneous platelet aggregation could
be detected after MK-0852 without (Fig. 1C) or with (Fig.
1D) collagen.
Cardiac hemodynamics. Baseline heart rate, mean arterial
pressure and diastolic coronary perfusion pressure were
similar in all experimental groups; changes due to coronary
occlusion and REP are summarized in Table 1. Hemody-
namic profiles were similar for all groups; heart rate in-
creased during coronary occlusion and then remained higher
than baseline values during REP. Rate-pressure product, an
indirect index of myocardial oxygen demand, was similar for
Figure 3. Systolic segment shortening (as % of baseline value) in the ischemic-reperfused myocardium during the experimental protocol (left panel); data
for the nonischemic myocardium is also shown (right panel). Controls (i.e., heparin; open circles); MK-0852 plus HEP (open squares); MK-0852 (open
triangles). Data are means 6 standard error of the mean.
Figure 4. Blood flow across the left ventricular wall from inner (End) to
outer (Epi) layers at baseline, 30 min coronary occlusion and at 180 min
coronary reperfusion in ischemic (upper panel) and nonischemic (lower
panel) regions. Controls (open circles); MK plus HEP (open squares);
MK (open triangles). Data are means 6 standard error of the mean.
Figure 5. Infarct size normalized to risk zone (left panel) and risk area as
percent of the left ventricle (right panel) for each treatment group; data
(mean 6 standard error of the mean) for individual hearts (open circles)
and mean values (closed squares) are shown. HEP 5 heparin; MK 5
MK-0852.
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each experimental group (Fig. 2); this suggests that myo-
cardial oxygen demand did not influence intergroup infarct
size results.
During ischemia significant hypokinesia occurred within
the ischemic zone (Fig. 3); during REP myocardial contrac-
tile function returned to 650% of baseline levels but
remained consistently lower afterwards. Fractional shorten-
ing in nonischemic myocardium remained constant; we did
not observe a compensatory increase in LV function in this
region as described previously (24).
In the infarct-related artery, peak reactive hyperemia
before ischemia was four-fold greater than control blood
flow levels; during REP it was attenuated by .50% (p #
0.05 vs. baseline) in all groups. Resting blood flow in
ischemic and nonischemic myocardium was similar as
shown in Figure 4. At 30 min coronary occlusion, blood
flow within the ischemic zone was 0.06 6 0.03, 0.07 6 0.05
and 0.08 6 0.05 mL/min/g in HEP, MK-0852 and
MK-0852 plus HEP treated dogs, respectively (p 5 NS
between groups). At the end of REP mean blood flow levels
were similar to baseline values for all experimental groups.
Infarct size data. Infarct size (normalized to risk area) is
shown in Figure 5; risk zone size was comparable for each
group. Infarct size was 32.4 6 2.8% in HEP-treated dogs
compared with 17.4 6 1.9% in MK-0852 (p 5 0.001 vs.
HEP) and 23.4 6 3.0% (p 5 0.04 vs. HEP) in MK-0852
plus HEP treated dogs. As such, MK-0852 without/with
concomitant HEP treatment provides significant cardiopro-
tection in this model of ischemia-reperfusion injury. Since
important variations in coronary collateral flow occur be-
tween dogs (25), we performed a multivariate analysis
taking into account both infarct size and ischemic zone
blood flow during coronary occlusion (Fig. 6); significant
cardioprotection (i.e., downward shift of the data vs. un-
treated dogs) was observed for both the MK-0852 and
MK-0852 plus HEP treated dogs.
DISCUSSION
In this study we documented significant cytoprotection with
MK-0852 administered at the onset of REP in a canine
preparation of acute ischemia-reperfusion injury. Cardio-
protection occurred independently of collateral blood flow
within the risk region, risk zone size or cardiac hemody-
namics (i.e., metabolic oxygen demand) and distribution of
myocardial blood flow.
Pathophysiological role for platelet aggregation. Platelet
activation and resultant aggregation are associated with
various cardio- and cerebrovascular thromboembolic disor-
ders including unstable angina, MI, stroke and atheroscle-
rosis (26–28). An ongoing pattern of platelet aggregation
within the infarct-related vascular bed may account for
progressive tissue injury during coronary reperfusion (29); as
such, antiplatelet treatments in the ischemia-reperfusion
setting could exert a protective influence at the level of the
microvasculature. Potential actions of MK-0852 with re-
ceptors other than the GPIIb/IIIa receptor and leukocyte-
endothelium adhesion interactions might also constitute a
cytoprotective mechanism against ischemia-reperfusion in-
jury.
Clinical studies. In the Platelet Receptor Inhibition in
Ischemic Syndrome Management in Patients Limited by
Unstable Signs and Symptoms (PRISM-PLUS) study,
combination therapy with tirofiban and HEP significantly
reduced the thrombus burden of the culprit lesion; this
resulted in less coronary artery obstruction and improved
distal flow in the infarct-related artery (8,30). Whether
concomitant thrombin inhibition with HEP is essential for
optimal efficacy of MK-0852 is not clear. Heparin has been
shown to directly affect leukocytes and expression of adhe-
sion molecules (31). In this study the combination of
therapy with MK-0852 and HEP, administered at the onset
of reperfusion, provided significant benefit against tissue
necrosis, but the observed protection was not greater than
that obtained with MK-0852 alone.
Earlier studies (21,31,32) speculated that inhibition of
platelet aggregation could favorably affect distribution of
blood flow within ischemic myocardium. Recent findings
document that combination therapy with abciximab plus
low-dose alteplase results in a more rapid restoration of
epicardial reperfusion and possibly improved perfusion of
microvessels; this resulted in greater ST resolution for
patients with Thrombolysis in Myocardial Infarction flow
grade 3 (33). In this study we cannot rule out a cytoprotec-
tive mechanism of the benefit of platelet inhibition inde-
pendent of any effect on myocardial perfusion.
Figure 6. Effect of MK-0852 on infarct size (% risk area) in dogs treated
with MK-0852 plus HEP (open square; p , 0.05 vs. CON) or MK-0852
(open triangle; p , 0.05 vs. CON). Coronary collateral blood flow
(mL/min/g) at 30-min coronary occlusion is also indicated. MK 5
MK-0852.
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Peak reactive hyperemia and LV contractile function.
The precise mechanisms responsible for reductions in post-
ischemic coronary flow reserve and LV contractile function
remain unknown but probably involve release of reactive
oxygen metabolites, microvascular plugging by platelets or
leukocytes and infiltration by neutrophils (34–36). Persis-
tently abnormal flow reserve in reperfused, viable myocar-
dium might be due to prolonged postischemic microvascular
stunning (37). In this study MK-0852 treatment did not
significantly improve either the peak reactive hyperemic
response of the infarct-related artery or contractile function
within the ischemic vascular bed.
Conclusions. We report that MK-0852, a cyclic heptapep-
tide antagonist of the platelet GPIIb/IIIa receptor, reduces
infarct size in a canine preparation of acute myocardial
ischemia-reperfusion injury. This cardioprotective effect was
unrelated to coronary collateral flow within the ischemic
zone. These data support the concept that inhibition of
platelet aggregation is cytoprotective; however, the specific
mechanism(s) for this cytoprotection remains undefined.
The findings of this study may be relevant to the clinical
management of patients with acute MI who are candidates
for reperfusion therapy.
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